Creation and assessment of a predictive model utilizing choroid plexus imaging from brain MRI for evaluating anti-TNF-α treatment responses in Crohn’s disease - Scorecard - MDSpire
Advertisement
Creation and assessment of a predictive model utilizing choroid plexus imaging from brain MRI for evaluating anti-TNF-α treatment responses in Crohn’s disease
Clinical Scorecard: Creation and assessment of a predictive model utilizing choroid plexus imaging from brain MRI for evaluating anti-TNF-α treatment responses in Crohn’s disease
At a Glance
Category
Detail
Condition
Crohn’s disease (CD)
Key Mechanisms
Involves immune dysregulation, genetic susceptibility, and environmental factors; associated with central nervous system alterations and the brain-gut axis.
Target Population
Adult patients with confirmed diagnosis of Crohn’s disease initiating anti-TNF-α therapy.
Care Setting
Gastroenterology department, hospital setting.
Key Highlights
Approximately 10% to 20% of patients exhibit primary non-response to anti-TNF-α therapy.
Secondary loss of response occurs in 23% to 46% of patients within one year.
Choroid plexus imaging may serve as a predictive biomarker for treatment response.
Guideline-Based Recommendations
Diagnosis
Diagnosis according to European Crohn’s and Colitis Organization guidelines.
Management
Initiation of anti-TNF-α therapy (infliximab or adalimumab) based on clinical indications.
Monitoring & Follow-up
Evaluate treatment response at 12 weeks and long-term outcomes at 48 weeks.
